Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

Abstract Introduction We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Methods This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52. Patients were randomised 2:1:1:1:2 to...

Full description

Bibliographic Details

Published in:	Dermatology and Therapy
Main Authors:	A. David Burden, Robert Bissonnette, Alexander A. Navarini, Masamoto Murakami, Akimichi Morita, Thomas Haeufel, Binqi Ye, Frank Baehner, Tadashi Terui
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-09-01
Subjects:	Adverse effects Dose-finding Palmoplantar psoriasis Palmoplantar pustular psoriasis Palmoplantar pustulosis Proof-of-concept
Online Access:	https://doi.org/10.1007/s13555-023-01002-1